The transformation to neuroendocrine prostate cancer (NEPC), a lethal form of prostate cancer, represents an increasing form of therapeutic resistance characterized by little or no AR activity and high levels of neuroendocrine markers [10,11,12]. This evidence concerns the gene AR and prostate cancer.